Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2865658 | 0.98 | CYP4F2 (0.38) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| SCHEMBL22680074 | 0.90 | PKM (0.39) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| SCHEMBL22680072 | 0.90 | PKM (0.39) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL22491839 | 0.88 | PKM (0.41) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL22655521 | 0.88 | PKM (0.41) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| SCHEMBL15910254 | 0.86 | CYP4F2 (0.39) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| SCHEMBL19071938 | 0.81 | ALDH1A1 (0.41) | CYP4F2CYP4A11MEN1KMT2ATHRB | |
| SCHEMBL25453903 | 0.81 | SLC6A2 (0.37) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| SCHEMBL1226998 | 0.80 | SLC6A1 (0.36) | CYP4F2CYP4A11MEN1KMT2ASLC6A2 | |
| SCHEMBL15361076 | 0.80 | CYP4F2 (0.36) | CYP4F2CYP4A11MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4384503-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118119595-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4359409-A1 | DEGRADER COMPOUNDS AND USES THEREOF | Calico Life Sciences LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1854793-A1 | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY | Japan Tobacco, Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20070167428-A1 | Thienopyrroles as antagonists of gnrh | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167428-A1 | Thienopyrroles as antagonists of gnrh | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| WO-2004080952-A1 | PHENYLSULFONAMIDE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE | BAYER HEALTHCARE AG (DE) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080952-A1 | PHENYLSULFONAMIDE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE | BAYER HEALTHCARE AG (DE) | 2004-09-23 | — | — | WO | disclosed |
| US-5614534-A | Derivatives of β, β-dimethyl-4-piperidineethanamine as inhibitors of the cholesterol biosynthesis | FOURNIER INDUSTRIE ET SANTE (FR) | 1997-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP4F2 1930/4885CYP4A11 828/4885MEN1 4517/4885 |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | CYP4F2 40/4885CYP4A11 3/4885MEN1 1083/4885 |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | CYP4F2 1297/4885CYP4A11 1550/4885MEN1 2212/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | CYP4F2 4760/4885CYP4A11 3911/4885MEN1 2199/4885 |
| US-20070167428-A1 | Thienopyrroles as antagonists of gnrh | GNRHR, PRLHR, TRHR | CYP4F2 732/4885CYP4A11 812/4885MEN1 923/4885 |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | SYK, BTK, ZAP70 | CYP4F2 3699/4885CYP4A11 3889/4885MEN1 4612/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP4F2 1930/4885CYP4A11 828/4885MEN1 4517/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CYP4F2 4760/4885CYP4A11 3911/4885MEN1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.